内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetologia：GIP(3-30)NH2是一种有效的GIP受体拮抗剂?

2018-04-24 MedSci MedSci原创

糖尿病葡萄糖
关注

近日，国际杂志 《Diabetologia》上在线发表一项关于GIP(3-30)NH2是在人类中一种有效的GIP受体拮抗剂的随机，双盲，安慰剂对照，交叉研究。 葡萄糖依赖型胰岛素多肽(GIP)是一种肠内内分泌K细胞分泌的内分泌激素，尽管具有一定的治疗效果，但关于人类GIP生理学尚不清楚。通过合适的GIP受体拮抗剂可促进该领域的进展。本研究首次对天然存在的GIP(3-30)NH2在体内和体外受

近日，国际杂志 《Diabetologia》上在线发表一项关于GIP(3-30)NH2是在人类中一种有效的GIP受体拮抗剂的随机，双盲，安慰剂对照，交叉研究。 葡萄糖依赖型胰岛素多肽(GIP)是一种肠内内分泌K细胞分泌的内分泌激素，尽管具有一定的治疗效果，但关于人类GIP生理学尚不清楚。通过合适的GIP受体拮抗剂可促进该领域的进展。本研究首次对天然存在的GIP(3-30)NH2在体内和体外受体研究中的拮抗特性开展了研究。 研究人员在瞬时转染的COS-7细胞中，在glucagon样肽1 (GLP-1)、glucagon-like peptide-2 (GLP-2)、胰高血糖素、分泌素和生长激素释放激素(GHRH)受体的同源受体结合和受体激活(cAMP积累)研究中评估GIP(3-30)NH2。临床研究纳入10名健康男性（合格标准：年龄20-30岁，HbA 1c低于6.5％[48 mmol/mol]和空腹血糖[FPG]低于7 mmol/l）。收集来自肘静脉套管的血浆和血清样品数据。作为主要结果，在高血糖钳夹实验中通过输注GIP（3-30）NH 2（800pmol kg -1 min-1），G

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1241347, encodeId=d2aa124134e38, content=求GIP的机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46b8139114, createdName=ms1000001253725139, createdTime=Sat Aug 27 10:22:54 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638576, encodeId=92b516385e697, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 02 12:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760658, encodeId=a3051e6065886, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 02 04:12:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511701, encodeId=2b641511e0119, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 26 06:12:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
    2022-08-27 ms1000001253725139

    求GIP的机制

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1241347, encodeId=d2aa124134e38, content=求GIP的机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46b8139114, createdName=ms1000001253725139, createdTime=Sat Aug 27 10:22:54 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638576, encodeId=92b516385e697, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 02 12:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760658, encodeId=a3051e6065886, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 02 04:12:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511701, encodeId=2b641511e0119, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 26 06:12:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
    2018-08-02 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1241347, encodeId=d2aa124134e38, content=求GIP的机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46b8139114, createdName=ms1000001253725139, createdTime=Sat Aug 27 10:22:54 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638576, encodeId=92b516385e697, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 02 12:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760658, encodeId=a3051e6065886, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 02 04:12:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511701, encodeId=2b641511e0119, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 26 06:12:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
    2018-07-02 ms5439512287675881

    #BET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1241347, encodeId=d2aa124134e38, content=求GIP的机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46b8139114, createdName=ms1000001253725139, createdTime=Sat Aug 27 10:22:54 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638576, encodeId=92b516385e697, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Aug 02 12:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760658, encodeId=a3051e6065886, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 02 04:12:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511701, encodeId=2b641511e0119, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Apr 26 06:12:00 CST 2018, time=2018-04-26, status=1, ipAttribution=)]
    2018-04-26 ms5236388012055669

    #拮抗剂#

    0

相关资讯

J Am Coll Cardiol：2型糖尿病患者心衰的患病率和发病率

2018年2月，发表在《J Am Coll Cardiol》的一项由美国和英国科学家进行的研究考察了2型糖尿病患者心血管结局试验中的心衰（HF）患病率和发病率。

PLos One：重磅！患有糖尿病与缺少维生素D有关！

研究人员进行的流行病学研究表明，缺乏维生素D的人患糖尿病的风险更大。科学家研究了903名健康成人(平均年龄74岁)的队列，从1997年到1999年期间，没有任何糖尿病前期或糖尿病的迹象，然后随访到2009年。在这些访问期间测量血液中的维生素D水平，以及空腹血糖和口服葡萄糖耐量。

Diabetologia：事件性糖尿病可能解释睡眠时间与冠心病事件之间的关系

近日，国际杂志 《Diabetologia》上在线发表一项关于事件性糖尿病可能解释睡眠时间与冠心病事件之间的关系的研究。 睡眠时间是糖尿病和冠心病的危险因素。本研究的主要目的是在性别特异性分析中调查糖尿病事件作为短期/长期睡眠时间与事件CHD之间关联的可能生物学机制。考虑到糖尿病是冠心病的主要危险因素，研究人员假设任何与睡眠持续时间相关的因素都不适用于事件糖尿病（“非糖尿病冠心病”）之前发生

Diabetes Care：糖尿病患者非心脏手术后心脑血管风险增加

研究数据显示，与无糖尿病患者相比，糖尿病患者在非心脏手术后发生主要心脑血管事件（MACCE）的风险更高，包括死亡率和急性心肌梗死；而且，无论是否有糖尿病，围术期卒中风险均增加。

BMJ：门诊I型糖尿病患者接受人工胰腺治疗对血糖的控制效果优于胰岛素疗法

研究认为，门诊I型糖尿病患者接受人工胰腺治疗可平稳安全的控制血糖，其效果优于胰岛素疗法

Nature：抗肥胖药物靶点研究获新突破

近日，中国科学院上海药物研究所吴蓓丽课题组在抗肥胖药物靶点的结构和功能研究方面取得重要进展，首次测定了神经肽Y受体Y1R分别与两种抑制剂结合的高分辨率三维结构，揭示了该受体与多种药物分子的相互作用机制，为治疗肥胖和糖尿病等疾病的药物研发提供了重要的依据。研究成果于北京时间4月19日在国际学术期刊《自然》（Nature）上在线发表。